Enes Erul

Enes Erul: Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors

Enes Erul, Oncology Fellow at Ankara Üniversitesi, shared on X:

“Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types.”

Enes Erul Enes Erul

Source: Enes Erul/X
cancer Cancer research cancer therapy clinical trial Enes Erul heavily treated patients HER2-mutant Medical Research objective response rate OncoDaily Oncology published study Research safety profile solid tumors Trastuzumab deruxtecan